[Priapism secondary to treatment due to cabergoline: the first description of this association].
De La Peña Zarzuelo
E
E
Hernández Cañas
V
V
Llorente Abarca
C
C
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011317:Priapism / Q000139:chemically induced*
D000970:Antineoplastic Agents; D004873:Ergolines; D000077465:Cabergoline